Nautilus Biotechnology (NAUT) Short term Debt (2020 - 2021)

Nautilus Biotechnology's (NAUT) quarterly Short term Debt came in at $30000.0 in Q1 2021, up 50.0% quarter-over-quarter from $20000.0 in Q3 2020.

Nautilus Biotechnology (NAUT) Short term Debt (2020 - 2021) Analysis & Trends

Nautilus Biotechnology has disclosed Short term Debt across 2 years of filings, most recently posting $30000.0 for Q1 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	Nautilus Biotechnology	289.99 Mn	194.12 Mn	-

Download Data